Targeting IL-4 for the Treatment of Atopic Dermatitis

Atopic dermatitis (AD) is an immune-mediated inflammatory skin disease characterized by a predominant type 2 immune response. Type 2 immunity is driven by multiple cytokines, including interleukin (IL)-4 and IL-13 that are considered central to AD pathogenesis and key therapeutic targets. The dual i...

Full description

Saved in:
Bibliographic Details
Published in:ImmunoTargets and therapy Vol. 9; pp. 151 - 156
Main Authors: Chiricozzi, Andrea, Maurelli, Martina, Peris, Ketty, Girolomoni, Giampiero
Format: Journal Article
Language:English
Published: Macclesfield Dove Medical Press Limited 01.01.2020
Taylor & Francis Ltd
Dove
Dove Medical Press
Subjects:
Advertising executives
Atopic dermatitis
B cells
Cytokines
Dendritic cells
Dermatitis
Dupilumab
Eczema
Gene expression
Granulocytes
il-4
il-4 inhibitor
Immune response
Immunotherapy
Inflammation
Interleukin 13
Interleukin 4
Interleukins
Kinases
Lymphocytes
Monoclonal antibodies
Neurons
pascolizumab
Pathogenesis
pitrakinra
Review
Skin
Skin diseases
ISSN:2253-1556, 2253-1556
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Atopic dermatitis (AD) is an immune-mediated inflammatory skin disease characterized by a predominant type 2 immune response. Type 2 immunity is driven by multiple cytokines, including interleukin (IL)-4 and IL-13 that are considered central to AD pathogenesis and key therapeutic targets. The dual inhibition of these two cytokines or the selective inhibition of IL-13 proved elevated efficacy in treating AD, whereas the selective inhibition of IL-4 has been poorly investigated as IL-4 inhibiting agents did not show any advance in clinical development programs. This review describes the pathogenic role of IL-4 in AD and briefly resumes the main features of compounds selectively blocking IL-4. Keywords: atopic dermatitis, IL-4, IL-4 inhibitor, dupilumab, pascolizumab, pitrakinra
AbstractList Atopic dermatitis (AD) is an immune-mediated inflammatory skin disease characterized by a predominant type 2 immune response. Type 2 immunity is driven by multiple cytokines, including interleukin (IL)‑4 and IL-13 that are considered central to AD pathogenesis and key therapeutic targets. The dual inhibition of these two cytokines or the selective inhibition of IL-13 proved elevated efficacy in treating AD, whereas the selective inhibition of IL-4 has been poorly investigated as IL-4 inhibiting agents did not show any advance in clinical development programs. This review describes the pathogenic role of IL-4 in AD and briefly resumes the main features of compounds selectively blocking IL-4.
Atopic dermatitis (AD) is an immune-mediated inflammatory skin disease characterized by a predominant type 2 immune response. Type 2 immunity is driven by multiple cytokines, including interleukin (IL)-4 and IL-13 that are considered central to AD pathogenesis and key therapeutic targets. The dual inhibition of these two cytokines or the selective inhibition of IL-13 proved elevated efficacy in treating AD, whereas the selective inhibition of IL-4 has been poorly investigated as IL-4 inhibiting agents did not show any advance in clinical development programs. This review describes the pathogenic role of IL-4 in AD and briefly resumes the main features of compounds selectively blocking IL-4. Keywords: atopic dermatitis, IL-4, IL-4 inhibitor, dupilumab, pascolizumab, pitrakinra
Andrea Chiricozzi,1,2 Martina Maurelli,3 Ketty Peris,1,2 Giampiero Girolomoni3 1Dermatologia, Dipartimento Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; 2Dermatologia, Università Cattolica del Sacro Cuore, Rome, Italy; 3Department of Medicine, Section of Dermatology, University of Verona, Verona, ItalyCorrespondence: Andrea ChiricozziDermatologia, Dipartimento Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome 00168, ItalyTel +39-339 5668320Fax +39-0761-571321Email chiricozziandrea@gmail.comAbstract: Atopic dermatitis (AD) is an immune-mediated inflammatory skin disease characterized by a predominant type 2 immune response. Type 2 immunity is driven by multiple cytokines, including interleukin (IL)‑4 and IL-13 that are considered central to AD pathogenesis and key therapeutic targets. The dual inhibition of these two cytokines or the selective inhibition of IL-13 proved elevated efficacy in treating AD, whereas the selective inhibition of IL-4 has been poorly investigated as IL-4 inhibiting agents did not show any advance in clinical development programs. This review describes the pathogenic role of IL-4 in AD and briefly resumes the main features of compounds selectively blocking IL-4.Keywords: atopic dermatitis, IL-4, IL-4 inhibitor, dupilumab, pascolizumab, pitrakinra
Atopic dermatitis (AD) is an immune-mediated inflammatory skin disease characterized by a predominant type 2 immune response. Type 2 immunity is driven by multiple cytokines, including interleukin (IL)‑4 and IL-13 that are considered central to AD pathogenesis and key therapeutic targets. The dual inhibition of these two cytokines or the selective inhibition of IL-13 proved elevated efficacy in treating AD, whereas the selective inhibition of IL-4 has been poorly investigated as IL-4 inhibiting agents did not show any advance in clinical development programs. This review describes the pathogenic role of IL-4 in AD and briefly resumes the main features of compounds selectively blocking IL-4.Atopic dermatitis (AD) is an immune-mediated inflammatory skin disease characterized by a predominant type 2 immune response. Type 2 immunity is driven by multiple cytokines, including interleukin (IL)‑4 and IL-13 that are considered central to AD pathogenesis and key therapeutic targets. The dual inhibition of these two cytokines or the selective inhibition of IL-13 proved elevated efficacy in treating AD, whereas the selective inhibition of IL-4 has been poorly investigated as IL-4 inhibiting agents did not show any advance in clinical development programs. This review describes the pathogenic role of IL-4 in AD and briefly resumes the main features of compounds selectively blocking IL-4.
Audience Academic
Author Chiricozzi, Andrea
Girolomoni, Giampiero
Maurelli, Martina
Peris, Ketty
Author_xml – sequence: 1
  givenname: Andrea
  orcidid: 0000-0002-6739-0387
  surname: Chiricozzi
  fullname: Chiricozzi, Andrea
– sequence: 2
  givenname: Martina
  orcidid: 0000-0001-7492-8010
  surname: Maurelli
  fullname: Maurelli, Martina
– sequence: 3
  givenname: Ketty
  surname: Peris
  fullname: Peris, Ketty
– sequence: 4
  givenname: Giampiero
  orcidid: 0000-0001-8548-0493
  surname: Girolomoni
  fullname: Girolomoni, Giampiero
BookMark eNptkluLEzEUgIOsuGvdJ__AgCCCTM1lcumLUNZboeCD43PIpCdtysykJhnBf2-6LbpdNnlISL7zJedwXqKrMYyA0GuC55Q08sOqbec_qMBM4mfohlLOasK5uHqwv0a3Ke1xGUo1hNIX6JoxLKggixvEWxO3kP24rVbruqlciFXeQdVGMHmAMVfBVcscDt5WnyAOJvvs0yv03Jk-we15naGfXz63d9_q9fevq7vluraCiFxTEBujCMa063DTNQvYkDKZkJ2UHKRdEJC4Ex3BBBwYjEFZwZV0bkEZCDZDq5N3E8xeH6IfTPyjg_H6_iDErTYxe9uD5qIojFOSEdoITjrTdA5kI7HoGFauuD6eXIepG2BjS27R9BfSy5vR7_Q2_NaSM7rAsgjenQUx_JogZT34ZKHvzQhhSpo2nCiumGAFffMI3YcpjqVU9xRnDWbkP7U1JQE_ulDetUepXgqmuFSy6GZo_gRV5gYGb0s3OF_OLwLePgjYgenzLoV-yj6M6RJ8fwJtDClFcP-KQbA-dpcu3aXP3VVo8oi2PpujtPzH90_G_AWgGc2k
CitedBy_id crossref_primary_10_1016_j_jaci_2022_03_010
crossref_primary_10_3390_microorganisms13081950
crossref_primary_10_1080_14786419_2024_2369908
crossref_primary_10_3390_ijms241814221
crossref_primary_10_1016_j_jid_2022_03_021
crossref_primary_10_3390_ijms22137227
crossref_primary_10_3389_fimmu_2023_1179355
crossref_primary_10_1016_j_bbi_2024_11_029
crossref_primary_10_1038_s41598_024_66601_0
crossref_primary_10_1016_j_smim_2025_101933
crossref_primary_10_1093_mmy_myaf079
crossref_primary_10_3390_molecules27134205
crossref_primary_10_1039_D4FO05988C
crossref_primary_10_3390_ijms26157286
crossref_primary_10_1016_j_jaci_2025_04_016
crossref_primary_10_1007_s10787_023_01214_z
crossref_primary_10_1016_j_jaci_2023_05_025
crossref_primary_10_3390_antiox11071344
crossref_primary_10_1016_j_cellimm_2021_104452
crossref_primary_10_4014_jmb_2312_12002
crossref_primary_10_1007_s12272_022_01369_3
crossref_primary_10_1080_1744666X_2021_1940962
crossref_primary_10_3389_fmed_2023_1165098
crossref_primary_10_1093_jimmun_vkaf049
crossref_primary_10_3390_ijms25031579
crossref_primary_10_1080_1744666X_2022_1993061
crossref_primary_10_1039_D4MD00301B
crossref_primary_10_3390_cimb46090547
crossref_primary_10_4049_jimmunol_2300629
crossref_primary_10_1080_1744666X_2023_2283585
crossref_primary_10_1007_s12325_022_02241_y
crossref_primary_10_29254_2077_4214_2024_4_175_146_153
crossref_primary_10_1016_j_colsurfb_2021_112244
crossref_primary_10_4103_2221_1691_357741
crossref_primary_10_3390_molecules26185655
crossref_primary_10_1002_adtp_202300096
crossref_primary_10_1155_2022_4520433
crossref_primary_10_1007_s00210_024_03722_3
crossref_primary_10_3389_fped_2023_1202100
crossref_primary_10_1093_burnst_tkae056
crossref_primary_10_3389_fimmu_2024_1361005
crossref_primary_10_4103_ijd_ijd_117_24
crossref_primary_10_3390_ijms26094230
crossref_primary_10_1038_s41598_022_11048_4
crossref_primary_10_3390_antiox12010027
crossref_primary_10_1111_all_15635
crossref_primary_10_3390_biomedicines10112700
crossref_primary_10_1002_slct_202500025
crossref_primary_10_1007_s12272_022_01421_2
crossref_primary_10_1007_s13555_025_01352_y
crossref_primary_10_1111_ced_15052
crossref_primary_10_3390_jcm11195633
crossref_primary_10_1007_s13555_025_01475_2
crossref_primary_10_1016_j_cyto_2023_156408
crossref_primary_10_3390_vaccines9030303
crossref_primary_10_1371_journal_pone_0320818
crossref_primary_10_3390_ijms23073977
crossref_primary_10_3390_ijms23126682
crossref_primary_10_1080_19768354_2021_1974938
crossref_primary_10_3389_fimmu_2024_1473105
crossref_primary_10_3389_fphar_2025_1593477
crossref_primary_10_1016_j_jid_2022_03_012
crossref_primary_10_1016_j_jaci_2022_08_026
crossref_primary_10_2478_acb_2023_0014
crossref_primary_10_1007_s13555_023_01081_0
crossref_primary_10_1016_j_intimp_2023_110495
crossref_primary_10_1136_sextrans_2021_055301
crossref_primary_10_3390_nu13093209
crossref_primary_10_1111_all_15967
crossref_primary_10_3390_plants13121704
crossref_primary_10_1038_s41573_023_00750_1
crossref_primary_10_3390_ijms24032102
crossref_primary_10_2147_DDDT_S484897
crossref_primary_10_3390_ijms24065635
crossref_primary_10_2147_JIR_S471963
crossref_primary_10_1080_14712598_2024_2435427
crossref_primary_10_1093_jimmun_vkae020
Cites_doi 10.4049/jimmunol.8.3.163
10.1172/JCI8205
10.1016/S0923-2494(05)80007-0
10.1016/j.jaci.2009.07.040
10.1002/1521-4141(200103)31:3<812::AID-IMMU812>3.0.CO;2-L
10.1016/j.jaci.2005.12.1345
10.1038/s41598-019-44253-9
10.1038/jid.2009.71
10.1080/09546634.2019.1682503
10.1056/NEJMoa021481
10.1111/exd.14034
10.1016/j.jaci.2010.11.043
10.1080/13543784.2020.1800639
10.1007/978-1-4899-0987-9_21
10.1016/S1043-4666(03)00221-7
10.1046/j.0022-202x.2001.01331.x
10.1111/all.13954
10.1067/mai.2001.117455
10.1046/j.0022-202x.2001.01484.x
10.1016/j.clim.2007.11.006
10.4049/jimmunol.171.6.3262
10.1016/j.jaci.2012.07.012
10.4049/jimmunol.177.4.2131
10.1038/jid.2008.88
10.1016/j.cell.2017.08.006
10.3390/ijms20164053
10.1016/0888-7543(89)90313-3
10.1046/j.1365-2249.2002.01973.x
10.1073/pnas.97.7.3406
10.1038/jid.2012.456
10.1586/1744666X.2016.1165093
10.1016/j.bbrc.2008.08.136
10.4049/jimmunol.150.12.5436
10.1093/intimm/dxh117
10.1073/pnas.85.18.6880
10.1172/JCI5669
10.1016/j.jaci.2009.12.934
10.1007/s00403-004-0455-6
10.1016/j.jaci.2017.01.011
10.1159/000447692
10.1172/JCI119496
10.4049/jimmunol.145.11.3796
10.4049/jimmunol.161.9.5027
10.1046/j.1365-2133.2000.03665.x
10.1038/jid.2013.503
10.1056/NEJMoa1610020
10.1016/j.jaci.2019.11.047
10.1016/j.jaci.2016.06.010
10.1101/gr.131029.111
10.1097/ACI.0000000000000553
10.1038/jid.2008.74
10.1080/08830180802430974
10.1016/j.jaci.2007.04.031
10.1016/S0140-6736(20)31286-1
10.1126/sciimmunol.aat1604
10.1111/all.14151
10.1046/j.1365-2745.2002.01383.x
10.1016/j.jaci.2015.01.020
10.1016/0091-6749(83)90546-8
10.1172/jci.insight.98006
10.1016/j.jaci.2017.07.006
10.1038/mi.2016.4
10.4049/jimmunol.0901860
ContentType Journal Article
Copyright COPYRIGHT 2020 Dove Medical Press Limited
2020. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2020 Chiricozzi et al.
2020 Chiricozzi et al. 2020 Chiricozzi et al.
Copyright_xml – notice: COPYRIGHT 2020 Dove Medical Press Limited
– notice: 2020. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2020 Chiricozzi et al.
– notice: 2020 Chiricozzi et al. 2020 Chiricozzi et al.
DBID AAYXX
CITATION
3V.
7XB
8C1
8FE
8FH
8FK
8G5
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
GUQSH
HCIFZ
LK8
M2O
M7P
MBDVC
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOA
DOI 10.2147/ITT.S260370
DatabaseName CrossRef
ProQuest Central (Corporate)
ProQuest Central (purchase pre-March 2016)
Public Health Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library (Alumni Edition)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Database
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
Research Library Prep
SciTech Premium Collection
ProQuest Biological Science Collection
ProQuest Research Library
Biological Science Database
Research Library (Corporate)
ProQuest Databases
ProQuest One Academic
ProQuest Publicly Available Content
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Open Access Full Text
DatabaseTitle CrossRef
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
Research Library (Alumni Edition)
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Research Library
ProQuest Central (New)
ProQuest Public Health
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest One Academic Eastern Edition
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database




MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Open Access Full Text
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: PIMPY
  name: Publicly Available Content Database
  url: http://search.proquest.com/publiccontent
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
DocumentTitleAlternate Chiricozzi et al
EISSN 2253-1556
EndPage 156
ExternalDocumentID oai_doaj_org_article_561efaf873124651ba4bfe74706b308f
PMC7532907
A638578758
10_2147_ITT_S260370
GroupedDBID 0YH
5VS
8C1
8FE
8FH
8G5
AAYXX
ABUWG
ADBBV
ADRAZ
AFFHD
AFKRA
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AQTUD
AZQEC
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
CCPQU
CITATION
DIK
DWQXO
EBD
FYUFA
GNUQQ
GROUPED_DOAJ
GUQSH
HCIFZ
HYE
IAO
IHR
IHW
IPNFZ
ITC
KQ8
LK8
M2O
M48
M7P
M~E
OK1
PGMZT
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQGLB
PQQKQ
PROAC
RIG
RPM
TDBHL
TUS
UKHRP
VDV
ALIPV
3V.
7XB
8FK
MBDVC
PKEHL
PQEST
PQUKI
PRINS
PUEGO
Q9U
7X8
5PM
ID FETCH-LOGICAL-c616t-2e6da81002bb04b49ed1d1d367b775e7c91e70b6b101efea00e8c6587ff923e63
IEDL.DBID DOA
ISICitedReferencesCount 89
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000573205300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 2253-1556
IngestDate Fri Oct 03 12:51:44 EDT 2025
Tue Nov 04 02:01:24 EST 2025
Fri Sep 05 07:09:24 EDT 2025
Sat Aug 23 12:55:44 EDT 2025
Tue Nov 11 10:39:33 EST 2025
Tue Nov 04 17:36:51 EST 2025
Thu May 22 21:23:19 EDT 2025
Sat Nov 29 06:37:26 EST 2025
Tue Nov 18 21:22:24 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Language English
License http://creativecommons.org/licenses/by-nc/3.0
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c616t-2e6da81002bb04b49ed1d1d367b775e7c91e70b6b101efea00e8c6587ff923e63
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0001-8548-0493
0000-0002-6739-0387
0000-0001-7492-8010
OpenAccessLink https://doaj.org/article/561efaf873124651ba4bfe74706b308f
PMID 33062619
PQID 2451534031
PQPubID 3933158
PageCount 6
ParticipantIDs doaj_primary_oai_doaj_org_article_561efaf873124651ba4bfe74706b308f
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7532907
proquest_miscellaneous_2451858363
proquest_journals_2451534031
gale_infotracmisc_A638578758
gale_infotracacademiconefile_A638578758
gale_healthsolutions_A638578758
crossref_primary_10_2147_ITT_S260370
crossref_citationtrail_10_2147_ITT_S260370
PublicationCentury 2000
PublicationDate 2020-01-01
PublicationDateYYYYMMDD 2020-01-01
PublicationDate_xml – month: 01
  year: 2020
  text: 2020-01-01
  day: 01
PublicationDecade 2020
PublicationPlace Macclesfield
PublicationPlace_xml – name: Macclesfield
PublicationTitle ImmunoTargets and therapy
PublicationYear 2020
Publisher Dove Medical Press Limited
Taylor & Francis Ltd
Dove
Dove Medical Press
Publisher_xml – name: Dove Medical Press Limited
– name: Taylor & Francis Ltd
– name: Dove
– name: Dove Medical Press
References He (ref36) 2009; 124
Howell (ref38) 2007; 120
Bhogal (ref49) 2008; 27
Roesner (ref8) 2019; 19
Lloyd (ref7) 2018; 3
Miake (ref52) 2019; 20
Gahr (ref32) 2011; 164
Werfel (ref4) 2016; 138
Ong (ref42) 2002; 347
Teraki (ref22) 2000; 143
Le Floc’h (ref56) 2020; 75
Oettgen (ref57) 1999; 104
Elias (ref3) 2008; 128
Newcomb (ref58) 2011; 127
Antoniu (ref65) 2010; 11
Leung (ref26) 1983; 71
Nishi (ref31) 2008; 376
Hijnen (ref24) 2013; 133
Andrew (ref28) 1998; 161
Pastore (ref53) 1997; 99
Tazawa (ref59) 2004; 295
Paller (ref5) 2017; 140
Werfel (ref13) 2009; 129
Campion (ref50) 2019; 28
Oetjen (ref51) 2017; 171
Brunner (ref6) 2017; 139
Hart (ref66) 2002; 130
Lee (ref34) 2004; 16
Bagnasco (ref10) 2016; 170
Pène (ref20) 1988; 85
Kong (ref1) 2012; 22
Nograles (ref46) 2010; 125
Calabrese (ref54) 2020
Nomura (ref43) 2003; 171
Simpson (ref61) 2016; 375
Pelly (ref17) 2016; 9
Cho (ref48) 2001; 116
Howell (ref44) 2006; 117
Izuhara (ref14) 1993; 144
Iezzi (ref21) 2006; 177
Czarnowicki (ref25) 2015; 136
Fargnoli (ref62) 2019
Okazaki (ref23) 2002; 32
Spergel (ref35) 1999; 103
Langan (ref68) 2020; 396
Kim (ref9) 2019; 9
Coca (ref2) 1923; 8
McKenzie (ref11) 1993; 150
Chan (ref33) 2001; 117
Keegan (ref15) 1994; 365
Berdyshev (ref41) 2018; 3
Roesner (ref19) 2016; 12
ref67
Xiao (ref30) 2003; 23
ref64
Gittler (ref27) 2012; 130
ref63
Howell (ref45) 2008; 128
Omori-Miyake (ref40) 2014; 134
Kim (ref37) 2008; 126
Bieber (ref55) 2020; 75
Swain (ref18) 1990; 145
Cho (ref47) 2001; 108
Sehra (ref39) 2010; 184
Huang (ref16) 2000; 97
Vulcano (ref29) 2001; 31
Tsoi (ref60) 2020; 145
Takahashi (ref12) 1989; 4
References_xml – volume: 8
  start-page: 163
  year: 1923
  ident: ref2
  publication-title: J Immunol
  doi: 10.4049/jimmunol.8.3.163
– volume: 104
  start-page: 829
  year: 1999
  ident: ref57
  publication-title: J Clin Invest
  doi: 10.1172/JCI8205
– volume: 144
  start-page: 584
  year: 1993
  ident: ref14
  publication-title: Res Immunol
  doi: 10.1016/S0923-2494(05)80007-0
– volume: 124
  start-page: 761
  year: 2009
  ident: ref36
  publication-title: J Allergy Clin Immunol
  doi: 10.1016/j.jaci.2009.07.040
– volume: 31
  start-page: 812
  year: 2001
  ident: ref29
  publication-title: Eur J Immunol
  doi: 10.1002/1521-4141(200103)31:3<812::AID-IMMU812>3.0.CO;2-L
– volume: 117
  start-page: 836
  year: 2006
  ident: ref44
  publication-title: J Allergy Clin Immunol
  doi: 10.1016/j.jaci.2005.12.1345
– volume: 9
  start-page: 7772
  year: 2019
  ident: ref9
  publication-title: Sci Rep
  doi: 10.1038/s41598-019-44253-9
– volume: 129
  start-page: 1878
  year: 2009
  ident: ref13
  publication-title: J Invest Dermatol
  doi: 10.1038/jid.2009.71
– start-page: 1
  year: 2019
  ident: ref62
  publication-title: J Dermatolog Treat
  doi: 10.1080/09546634.2019.1682503
– volume: 347
  start-page: 1151
  year: 2002
  ident: ref42
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa021481
– volume: 28
  start-page: 1501
  year: 2019
  ident: ref50
  publication-title: Exp Dermatol
  doi: 10.1111/exd.14034
– volume: 127
  start-page: 1006
  year: 2011
  ident: ref58
  publication-title: J Allergy Clin Immunol
  doi: 10.1016/j.jaci.2010.11.043
– start-page: 1
  year: 2020
  ident: ref54
  publication-title: Expert Opin Investig Drugs
  doi: 10.1080/13543784.2020.1800639
– volume: 11
  start-page: 1286
  year: 2010
  ident: ref65
  publication-title: Curr Opin Investig Drugs
– volume: 365
  start-page: 211
  year: 1994
  ident: ref15
  publication-title: Adv Exp Med Biol
  doi: 10.1007/978-1-4899-0987-9_21
– volume: 23
  start-page: 126
  year: 2003
  ident: ref30
  publication-title: Cytokine
  doi: 10.1016/S1043-4666(03)00221-7
– volume: 116
  start-page: 658
  year: 2001
  ident: ref48
  publication-title: J Invest Dermatol
  doi: 10.1046/j.0022-202x.2001.01331.x
– volume: 75
  start-page: 54
  year: 2020
  ident: ref55
  publication-title: Allergy
  doi: 10.1111/all.13954
– volume: 108
  start-page: 269
  year: 2001
  ident: ref47
  publication-title: J Allergy Clin Immunol
  doi: 10.1067/mai.2001.117455
– volume: 117
  start-page: 977
  year: 2001
  ident: ref33
  publication-title: J Invest Dermatol
  doi: 10.1046/j.0022-202x.2001.01484.x
– volume: 126
  start-page: 332
  year: 2008
  ident: ref37
  publication-title: Clin Immunol
  doi: 10.1016/j.clim.2007.11.006
– volume: 171
  start-page: 3262
  year: 2003
  ident: ref43
  publication-title: J Immunol
  doi: 10.4049/jimmunol.171.6.3262
– volume: 130
  start-page: 1344
  year: 2012
  ident: ref27
  publication-title: J Allergy Clin Immunol
  doi: 10.1016/j.jaci.2012.07.012
– volume: 177
  start-page: 2131
  year: 2006
  ident: ref21
  publication-title: J Immunol
  doi: 10.4049/jimmunol.177.4.2131
– volume: 128
  start-page: 1067
  year: 2008
  ident: ref3
  publication-title: J Invest Dermatol
  doi: 10.1038/jid.2008.88
– volume: 171
  start-page: 217
  year: 2017
  ident: ref51
  publication-title: Cell
  doi: 10.1016/j.cell.2017.08.006
– volume: 20
  start-page: 4053
  year: 2019
  ident: ref52
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms20164053
– volume: 4
  start-page: 47
  year: 1989
  ident: ref12
  publication-title: Genomics
  doi: 10.1016/0888-7543(89)90313-3
– volume: 130
  start-page: 93
  year: 2002
  ident: ref66
  publication-title: Clin Exp Immunol
  doi: 10.1046/j.1365-2249.2002.01973.x
– volume: 97
  start-page: 3406
  year: 2000
  ident: ref16
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.97.7.3406
– volume: 133
  start-page: 973
  year: 2013
  ident: ref24
  publication-title: J Invest Dermatol
  doi: 10.1038/jid.2012.456
– volume: 164
  start-page: 586
  year: 2011
  ident: ref32
  publication-title: Br J Dermatol
– volume: 12
  start-page: 787
  year: 2016
  ident: ref19
  publication-title: Expert Rev Clin Immunol
  doi: 10.1586/1744666X.2016.1165093
– volume: 376
  start-page: 234
  year: 2008
  ident: ref31
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2008.08.136
– ident: ref64
– volume: 150
  start-page: 5436
  year: 1993
  ident: ref11
  publication-title: J Immunol
  doi: 10.4049/jimmunol.150.12.5436
– volume: 16
  start-page: 1155
  year: 2004
  ident: ref34
  publication-title: Int Immunol
  doi: 10.1093/intimm/dxh117
– volume: 85
  start-page: 6880
  year: 1988
  ident: ref20
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.85.18.6880
– volume: 103
  start-page: 1103
  year: 1999
  ident: ref35
  publication-title: J Clin Invest
  doi: 10.1172/JCI5669
– volume: 125
  start-page: 744
  year: 2010
  ident: ref46
  publication-title: J Allergy Clin Immunol
  doi: 10.1016/j.jaci.2009.12.934
– volume: 295
  start-page: 459
  year: 2004
  ident: ref59
  publication-title: Arch Dermatol Res
  doi: 10.1007/s00403-004-0455-6
– volume: 139
  start-page: S65
  year: 2017
  ident: ref6
  publication-title: J Allergy Clin Immunol
  doi: 10.1016/j.jaci.2017.01.011
– volume: 170
  start-page: 122
  year: 2016
  ident: ref10
  publication-title: Int Arch Allergy Immunol
  doi: 10.1159/000447692
– volume: 99
  start-page: 3009
  year: 1997
  ident: ref53
  publication-title: J Clin Invest
  doi: 10.1172/JCI119496
– volume: 145
  start-page: 3796
  year: 1990
  ident: ref18
  publication-title: J Immunol
  doi: 10.4049/jimmunol.145.11.3796
– volume: 161
  start-page: 5027
  year: 1998
  ident: ref28
  publication-title: J Immunol
  doi: 10.4049/jimmunol.161.9.5027
– volume: 143
  start-page: 373
  year: 2000
  ident: ref22
  publication-title: Br J Dermatol
  doi: 10.1046/j.1365-2133.2000.03665.x
– volume: 134
  start-page: 1342
  year: 2014
  ident: ref40
  publication-title: J Invest Dermatol
  doi: 10.1038/jid.2013.503
– volume: 375
  start-page: 2335
  year: 2016
  ident: ref61
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1610020
– volume: 145
  start-page: 1406
  year: 2020
  ident: ref60
  publication-title: J Allergy Clin Immunol
  doi: 10.1016/j.jaci.2019.11.047
– ident: ref63
– volume: 138
  start-page: 336
  year: 2016
  ident: ref4
  publication-title: J Allergy Clin Immunol
  doi: 10.1016/j.jaci.2016.06.010
– ident: ref67
– volume: 22
  start-page: 850
  year: 2012
  ident: ref1
  publication-title: Genome Res
  doi: 10.1101/gr.131029.111
– volume: 19
  start-page: 319
  year: 2019
  ident: ref8
  publication-title: Curr Opin Allergy Clin Immunol
  doi: 10.1097/ACI.0000000000000553
– volume: 128
  start-page: 2248
  year: 2008
  ident: ref45
  publication-title: J Invest Dermatol
  doi: 10.1038/jid.2008.74
– volume: 27
  start-page: 472
  year: 2008
  ident: ref49
  publication-title: Int Rev Immunol
  doi: 10.1080/08830180802430974
– volume: 120
  start-page: 150
  year: 2007
  ident: ref38
  publication-title: J Allergy Clin Immunol
  doi: 10.1016/j.jaci.2007.04.031
– volume: 396
  start-page: 345
  year: 2020
  ident: ref68
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)31286-1
– volume: 3
  start-page: eaat1604
  year: 2018
  ident: ref7
  publication-title: Sci Immunol
  doi: 10.1126/sciimmunol.aat1604
– volume: 75
  start-page: 1188
  year: 2020
  ident: ref56
  publication-title: Allergy
  doi: 10.1111/all.14151
– volume: 32
  start-page: 1236
  year: 2002
  ident: ref23
  publication-title: Clin Exp Allergy
  doi: 10.1046/j.1365-2745.2002.01383.x
– volume: 136
  start-page: 104
  year: 2015
  ident: ref25
  publication-title: J Allergy Clin Immunol
  doi: 10.1016/j.jaci.2015.01.020
– volume: 71
  start-page: 47
  year: 1983
  ident: ref26
  publication-title: J Allergy Clin Immunol
  doi: 10.1016/0091-6749(83)90546-8
– volume: 3
  start-page: e98006
  year: 2018
  ident: ref41
  publication-title: JCI Insight
  doi: 10.1172/jci.insight.98006
– volume: 140
  start-page: 633
  year: 2017
  ident: ref5
  publication-title: J Allergy Clin Immunol
  doi: 10.1016/j.jaci.2017.07.006
– volume: 9
  start-page: 1407
  year: 2016
  ident: ref17
  publication-title: Mucosal Immunol
  doi: 10.1038/mi.2016.4
– volume: 184
  start-page: 3186
  year: 2010
  ident: ref39
  publication-title: J Immunol
  doi: 10.4049/jimmunol.0901860
SSID ssj0000884122
Score 2.4246616
SecondaryResourceType review_article
Snippet Atopic dermatitis (AD) is an immune-mediated inflammatory skin disease characterized by a predominant type 2 immune response. Type 2 immunity is driven by...
Andrea Chiricozzi,1,2 Martina Maurelli,3 Ketty Peris,1,2 Giampiero Girolomoni3 1Dermatologia, Dipartimento Scienze Mediche e Chirurgiche, Fondazione...
SourceID doaj
pubmedcentral
proquest
gale
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 151
SubjectTerms Advertising executives
Atopic dermatitis
B cells
Cytokines
Dendritic cells
Dermatitis
Dupilumab
Eczema
Gene expression
Granulocytes
il-4
il-4 inhibitor
Immune response
Immunotherapy
Inflammation
Interleukin 13
Interleukin 4
Interleukins
Kinases
Lymphocytes
Monoclonal antibodies
Neurons
pascolizumab
Pathogenesis
pitrakinra
Review
Skin
Skin diseases
SummonAdditionalLinks – databaseName: Biological Science Database
  dbid: M7P
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagcODCGxEoYKSqSKhpE8exkxNaHhWVqmolAurNsh0bVkLJsrtF6r9nxvHuNoC4oNziiRLbM-PPk_E3hOw5LPsmrU9t3hYpF9ylhoky1ZkxhrWiFYG34MupPDurzs_raQy4LWNa5donBkfd9hZj5EeMw8pbcNDBN_MfKVaNwr-rsYTGdXIDWRJYSN2bbmIsYEE8Z2w4locFeY5OmubwE0D4AosTX1mIAl__n17590zJK0vP8Z3__ei75HYEnXQyaMk9cs1198n-dGCtvjygzfYQ1vKA7tPpls_68gEpm5AtDmscPTlNOQWYSwE20mado057Tyerfj6z9L0bIPBs-ZB8Pv7QvPuYxmoLqRW5WKXMiVZXyMhqTMYNr12bw1UIaaQsnbR17mRmhAEjdt7pLHOVBfwivQeQ6ETxiOx0feceE-q1sVobQDOm5bVu67J2FWthd1kb40WRkNfroVc2UpFjRYzvCrYkOE8K5knFeUrI3kZ4PjBw_F3sLc7hRgRps8ONfvFVRStUABad176SBcAaUeZGc-Md7KgyYYqs8gl5gRqghjOoG-NXE_BS6NrKKiGvggSaP3yy1fEUA3QcibRGkrsjSTBbO25eq4yKbmOptvqSkJebZnwSU-E6118MMlVZFTiMcqSdo76PW7rZt0AdDptTVmfyyb9f_pTcYhhWCJGmXbKzWly4Z-Sm_Qnas3gebOwXcDAwpw
  priority: 102
  providerName: ProQuest
Title Targeting IL-4 for the Treatment of Atopic Dermatitis
URI https://www.proquest.com/docview/2451534031
https://www.proquest.com/docview/2451858363
https://pubmed.ncbi.nlm.nih.gov/PMC7532907
https://doaj.org/article/561efaf873124651ba4bfe74706b308f
Volume 9
WOSCitedRecordID wos000573205300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Open Access Full Text
  customDbUrl:
  eissn: 2253-1556
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000884122
  issn: 2253-1556
  databaseCode: DOA
  dateStart: 20120101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2253-1556
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000884122
  issn: 2253-1556
  databaseCode: M~E
  dateStart: 20120101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVPQU
  databaseName: Biological Science Database
  customDbUrl:
  eissn: 2253-1556
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000884122
  issn: 2253-1556
  databaseCode: M7P
  dateStart: 20120101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/biologicalscijournals
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 2253-1556
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000884122
  issn: 2253-1556
  databaseCode: BENPR
  dateStart: 20120101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Public Health Database
  customDbUrl:
  eissn: 2253-1556
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000884122
  issn: 2253-1556
  databaseCode: 8C1
  dateStart: 20120101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/publichealth
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Publicly Available Content Database
  customDbUrl:
  eissn: 2253-1556
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000884122
  issn: 2253-1556
  databaseCode: PIMPY
  dateStart: 20120101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/publiccontent
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Research Library
  customDbUrl:
  eissn: 2253-1556
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000884122
  issn: 2253-1556
  databaseCode: M2O
  dateStart: 20120101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/pqrl
  providerName: ProQuest
– providerCode: PRVAWR
  databaseName: Taylor & Francis Open Access
  customDbUrl:
  eissn: 2253-1556
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000884122
  issn: 2253-1556
  databaseCode: 0YH
  dateStart: 20121201
  isFulltext: true
  titleUrlDefault: https://www.tandfonline.com
  providerName: Taylor & Francis
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3fa9QwHA86ffBF_InVeUYYE2RlbZMm6eNtbniwnUWrnE8hSRN2IL2xuwn77_0m6d2uKvgihTw030L77ffHJ-03ny9Ce9a3fePGpSZvSUoZtakuWJmqTGtdtKxlgbfg2xmfTsVsVtVbrb58TVikB46KO4T8bp1yghPIRKzMtaLaWQDBGdMkE85H34xXW4upEIOFoHn4hQD2SlJImixuzvNteQ49o9ISgDzxLYq30lFg7f8zNv9eL7mVgE4foYc9csTjeMeP0R3bPUH7daSevjnAze1OquUB3sf1LSn1zVNUNqHkGxIVnpylFANWxYD9cLMuNMcLh8erxeXc4A824tj58hn6enrSHH9M-5YJqWE5W6WFZa0SnlZV64xqWtk2h4MwrjkvLTdVbnmmmQZPtM6qLLPCAAjhzgHSs4w8RzvdorMvEHZKG6U0QBLd0kq1VVlZUbSwRKy0dowk6P1ac9L0fOK-rcUPCesKr2Y5aRr5Jao5QXsb4ctIo_F3sSP_CjYinvs6nACLkL1FyH9ZRILe-Bco40bSjQfLMYQaH59KkaB3QcL7MNyyUf1WBHhwz4Y1kNwdSILvmeH02khk7_tLWVDAiIRCtEzQ2820v9LXs3V2cR1lRCmIVyMfGNfg2Ycz3fwi8H_DCrOoMv7yfyjrFXpQ-C8I4aPSLtpZXV3b1-i--Qk2djVCd_lMwCiO8xG6d3QyrT-PgqPBeF588iOvYaaenNfffwFNsSu3
linkProvider Directory of Open Access Journals
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3db9MwED-NDgle-EYUBjPSGBJaWOI4dvKAUGFMq9ZVlQjTeDKxY0Ml1JS2A_Wf4m_knI92AcTbHlDf6msbJ7_73Z17HwA7xo19E9p6OshDj3FmPEV55GW-UormPOdl34LTgRgO47OzZLQBP5taGJdW2XBiSdR5od0Z-T5laHlDhhh8Pf3mualR7t_VZoRGBYtjs_yBIdv8Vf8An-8zSg_fpW-PvHqqgKd5wBceNTzPYtd5VCmfKZaYPMBXyIUSIjJCJ4ERvuIKwWqsyXzfxBrttLAWnSHDQ_zeK7DJHNg7sDnqn4w-rk51UGdZQGlVCOhGAO330_TlewwaQjcO-YLpKycE_GkHfs_NvGDsDm_-b7fpFtyo3WrSq_TgNmyYyR3YHVV9uZd7JF2Xmc33yC4ZrTt2L-9ClJb58GjFSX_gMYKOPEHHmKRNFj4pLOktiulYkwNTOfnj-T34cClbug-dSTExD4DYTOksU-ivqZwlWZ5EiYlpjvFzopTlYRdeNI9a6rrZupv58VVi0OVwIREXssZFF3ZWwtOqx8jfxd44zKxEXGPw8o1i9lnWPCPRHTY2s7EI0XHjUaAypqzBmNHnKvRj24VthzhZVdmu6E32kIcdeUdxF56XEo7g8JJ1Vtdp4MZdq7CW5FZLEolJt5cbiMqaGOdyjc8uPF0tu0-6ZL-JKc4rmTiKQ3cbRUsbWntvr0zGX8rm6Bh-08QXD__949tw7Sg9GchBf3j8CK5Td4hSnqttQWcxOzeP4ar-jkiaPak1nMCny9aWX3izj0A
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lj9MwEB4tXYS48EYUFtZIyyKhDU0cx0kOCBVKRbWlikRYLScTOzZUQk1pu6D-NX4d4zzaDSBue0C91dM2Tr6Z-cadB8CBtmPfQmUc5eW-wzjTjqQ8cDJXSklznvOyb8HJOJxMotPTONmBn00tjE2rbGxiaajzQtkz8h5l6Hl9hhjsmTotIhkMX86_OXaClP2ntRmnUUHkWK9_YPi2fDEa4LN-QunwTfr6rVNPGHAU9_jKoZrnWWS7kErpMslinXv48nkowzDQoYo9HbqSSwSuNjpzXR0p9NmhMUiMNPfxey_BLlJyRjuwm4zeJR83Jzyov8yjtCoKtOOAeqM0ff4eAwjfjkY-5wbLaQF_-oTf8zTPOb7h9f_5lt2AazXdJv1KP27Cjp7dgsOk6te9PiLptvxseUQOSbLt5L2-DUFa5smjdyejscMIEnyChJmkTXY-KQzpr4r5VJGBrsj_dHkHPlzIlu5CZ1bM9D0gJpMqyyTyOJmzOMvjINYRzTGujqU03O_Cs-axC1U3YbezQL4KDMYsRgRiRNQY6cLBRnhe9R75u9gri5-NiG0YXr5RLD6L2v4IpMnaZCYKfSR0PPBkxqTRCFyXS9-NTBf2LfpEVX27MXuij_bZGvUg6sLTUsIaPrxkldX1G7hx20KsJbnXkkSDpdrLDVxFbTCXYovVLjzeLNtP2iTAmS7OKpkoiHx7G8OWZrT23l6ZTb-UTdMxLKexG97_94_vwxVUETEeTY4fwFVqz1bK47Y96KwWZ_ohXFbfEUiLR7WyE_h00cryC54jmAA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Targeting+IL-4+for+the+Treatment+of+Atopic+Dermatitis&rft.jtitle=ImmunoTargets+and+therapy&rft.au=Chiricozzi%2C+Andrea&rft.au=Peris%2C+Ketty&rft.au=Maurelli%2C+Martina&rft.au=Girolomoni%2C+Giampiero&rft.date=2020-01-01&rft.pub=Dove+Medical+Press+Limited&rft.issn=2253-1556&rft.eissn=2253-1556&rft.volume=9&rft.spage=151&rft_id=info:doi/10.2147%2Fitt.s260370&rft.externalDBID=n%2Fa&rft.externalDocID=A638578758
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2253-1556&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2253-1556&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2253-1556&client=summon